23/07/2021at 15:02

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Christian Grøndahl, co-founder and CEO of Snipr Biome | Foto: Snipr Biome/pr

Pharma & biotech

Snipr Biome shelves lead candidate: "It’s hard to make money within AMR"

There are fundamental market flaws holding back the development of new antibiotics, acknowledges Snipr Biome CEO Christian Grøndahl, as the company pivots to gene technology.

For subscribers

Foto: Brendan Mcdermid/Reuters/Ritzau Scanpix

Pharma & biotech

Merck sues US, calling move to cut drug prices "extortion"

For subscribers

Pharma & biotech

Takeda, Eli Lilly must defend racketeering suit over diabetes drug, judge rules

For subscribers

Foto: George Frey/Reuters/Ritzau Scanpix

Pharma & biotech

UK looks to expand obesity-drug access with pilot program

For subscribers

Foto: Anna Gordon/Reuters/Ritzau Scanpix

Pharma & biotech

EU Commission approves first RSV vaccine for people over 60

For subscribers

Regulation

Denmark warns against overtreatment with Ozempic

For subscribers

Obesity shot frenzy makes Eli Lilly world’s most valuable drugmaker

After a strong May, Eli Lilly surpasses Johnson & Johnson on market values, becoming the biggest pharma firm in the world.

For subscribers

Pharma & biotech

Snipr Biome shelves lead candidate: "It’s hard to make money within AMR"

There are fundamental market flaws holding back the development of new antibiotics, acknowledges Snipr Biome CEO Christian Grøndahl, as the company pivots to gene technology.

For subscribers

Regulation